deoxycytidine

Summary

Top Publications

  1. ncbi FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
  2. ncbi Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
  3. ncbi Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole, 10, Orbassano Torino, Italy
    J Clin Oncol 26:3543-51. 2008
  4. pmc Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
    Kenneth P Olive
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
    Science 324:1457-61. 2009
  5. ncbi Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
  6. ncbi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
  7. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
  8. pmc Pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
    Lancet 363:1049-57. 2004
  9. pmc Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
    Yiwei Li
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 69:6704-12. 2009
  10. ncbi Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
    Juan Valle
    Christie Hospital, Manchester, United Kingdom
    N Engl J Med 362:1273-81. 2010

Detail Information

Publications359 found, 100 shown here

  1. ncbi FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
    ....
  2. ncbi Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...
  3. ncbi Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole, 10, Orbassano Torino, Italy
    J Clin Oncol 26:3543-51. 2008
    ..Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting...
  4. pmc Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
    Kenneth P Olive
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
    Science 324:1457-61. 2009
    ..Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer...
  5. ncbi Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
    ..We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer...
  6. ncbi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  7. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
    ..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...
  8. pmc Pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
    Lancet 363:1049-57. 2004
    ..However, new therapeutic strategies based on the molecular biology of pancreatic cancer seem to hold the greatest promise...
  9. pmc Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
    Yiwei Li
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 69:6704-12. 2009
    ....
  10. ncbi Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
    Juan Valle
    Christie Hospital, Manchester, United Kingdom
    N Engl J Med 362:1273-81. 2010
    ..After we found an improvement in progression-free survival, the trial was extended to the phase 3 trial reported here...
  11. pmc Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    Timothy S Maughan
    School of Medicine, Cardiff University, Cardiff, UK
    Lancet 377:2103-14. 2011
    ....
  12. ncbi Capecitabine and oxaliplatin for advanced esophagogastric cancer
    David Cunningham
    Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom
    N Engl J Med 358:36-46. 2008
    ..We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer...
  13. ncbi Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    Helmut Oettle
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    JAMA 297:267-77. 2007
    ..The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists...
  14. ncbi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  15. ncbi Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
    Ulrich Gatzemeier
    Zentrum fur Pneumologie und Thoraxchirurgie, Krankenhaus D LVA, Germany
    J Clin Oncol 25:1545-52. 2007
    ....
  16. pmc Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway
    Zhiwei Wang
    Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer Res 69:2400-7. 2009
    ....
  17. ncbi Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 18:317-23. 2007
    ..To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell lung cancer (NSCLC) by a non-inferiority design...
  18. pmc Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
    Hedy Lee Kindler
    University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    J Clin Oncol 28:3617-22. 2010
    ..These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients...
  19. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
    ..Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium...
  20. ncbi A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
    David Cameron
    University of Leeds, Leeds, England, UK
    Breast Cancer Res Treat 112:533-43. 2008
    ..Updated efficacy and initial biomarker results from this trial are reported...
  21. ncbi Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2
    Jean Pierre Gerard
    Centre Antoine Lacassagne, 06189 Nice Cedex 2, France
    J Clin Oncol 28:1638-44. 2010
    ..Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin...
  22. ncbi Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
    David Cunningham
    Royal Marsden National HealthService NHS Foundation Trust, London and Surrey, United Kingdom
    J Clin Oncol 27:5513-8. 2009
    ..This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP)...
  23. ncbi Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Jim Cassidy
    Glasgow University, Garscube Estate, Switchback Rd, Glasgow, Scotland
    J Clin Oncol 26:2006-12. 2008
    ..To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC)...
  24. ncbi Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research UNSW, 5St Vincent s Centre for Applied Medical Research, Sydney, Australia
    Clin Infect Dis 49:1591-601. 2009
    ..Which fixed-dose-combination tablet is more effective and safe is uncertain...
  25. ncbi Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial
    John P Neoptolemos
    Liverpool Cancer Research UK Cancer Trials Unit, Cancer Research UK Centre, University of Liverpool, Fifth Floor, UCD Bldg, Daulby Street, Liverpool, L69 3GA, United Kingdom
    JAMA 304:1073-81. 2010
    ..Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer...
  26. pmc Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    Philip A Philip
    Wayne State University, Karmanos Cancer Institute, GI Oncology, Detroit, MI 48201, USA
    J Clin Oncol 28:3605-10. 2010
    ..This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor...
  27. pmc Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice
    Paul W Denton
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America
    PLoS Med 5:e16. 2008
    ..Given the importance of this route of transmission, we investigated the susceptibility of humanized mice to intravaginal HIV-1 infection...
  28. pmc Antiretroviral therapies in women after single-dose nevirapine exposure
    Shahin Lockman
    Brigham and Women s Hospital, Boston, MA, USA
    N Engl J Med 363:1499-509. 2010
    ..Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus...
  29. pmc Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine
    Urvi M Parikh
    Laboratory Branch, Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    J Virol 83:10358-65. 2009
    ..Thus, single drugs with durable antiviral activity can provide highly effective topical prophylaxis and overcome the need for noncoital use or for drug combinations which are more complex and costly to formulate and approve...
  30. ncbi Development and characterization of gemcitabine-resistant pancreatic tumor cells
    Ami N Shah
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Ann Surg Oncol 14:3629-37. 2007
    ..To study the mechanisms of chemoresistance in pancreatic cancer we developed two gemcitabine-resistant pancreatic cancer cell lines...
  31. ncbi Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
    Alexander Arlt
    1Laboratory of Molecular Gastroenterology and Hepatology, 1st Department of Medicine, University of Kiel, Germany
    Oncogene 22:3243-51. 2003
    ....
  32. ncbi BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
    Miquel Taron
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Hum Mol Genet 13:2443-9. 2004
    ..020) compared with those in the top quartile. BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer...
  33. pmc Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial
    Patrick J Loehrer
    Indiana University Melvin and Bren Simon Cancer Center, 980 West Walnut St, Suite C528, Indianapolis, IN 46202, USA
    J Clin Oncol 29:4105-12. 2011
    ..The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer...
  34. ncbi Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial
    C Louvet
    Service d Oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    J Clin Oncol 23:3509-16. 2005
    ..Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer...
  35. pmc Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
    Craig Reynolds
    US Oncology, The Woodlands, TX, USA
    J Clin Oncol 27:5808-15. 2009
    ....
  36. ncbi Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
    Hedy L Kindler
    University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA
    Lancet Oncol 12:256-62. 2011
    ..On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial...
  37. ncbi Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg Leuven, Digestive Oncology Unit, Herestraat 49, B 3000 Leuven, Belgium
    J Clin Oncol 27:2231-7. 2009
    ..Phase II results for bevacizumab plus gemcitabine provided the rationale for a phase III trial of gemcitabine-erlotinib plus bevacizumab or placebo...
  38. pmc Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
    ..Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can further improve treatment efficacy...
  39. pmc Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Joseph A Sparano
    Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Clin Oncol 28:3256-63. 2010
    ....
  40. pmc Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:193-8. 2009
    ..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine...
  41. ncbi Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study
    Frank A Post
    King s College London, London, United Kingdom
    J Acquir Immune Defic Syndr 55:49-57. 2010
    ..Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have comprehensively compared their safety profiles...
  42. ncbi Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
    ..The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting...
  43. pmc Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
    Christopher H Crane
    Dept of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX
    J Clin Oncol 29:3037-43. 2011
    ..This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC)...
  44. ncbi Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
    Hans Jurgen Stellbrink
    Infektions Medizinisches Centrum Hamburg Study Center, Hamburg, Germany
    Clin Infect Dis 51:963-72. 2010
    ..Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles...
  45. pmc Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
    Daniel Habermehl
    Department of Radiation Oncology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Radiat Oncol 7:28. 2012
    ..To evaluate efficacy and secondary resectability in patients with locally advanced pancreatic cancer (LAPC) treated with neoadjuvant chemoradiotherapy (CRT)...
  46. ncbi Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
    Shin Nakahira
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    Int J Cancer 120:1355-63. 2007
    ..016). RRM1 should be a key molecule in gemcitabine resistance in human pancreatic cancer through both in vitro and clinical models. RRM1 may have the potential as predictor and modulator of gemcitabine treatment...
  47. pmc In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells
    Stephanie E Combs
    Department of Radiation Oncology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Radiat Oncol 7:9. 2012
    ..To evaluate the cytotoxic effect of carbon ion radiotherapy and chemotherapy in glioblastoma cells in vitro...
  48. ncbi Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer
    Reginald V N Lord
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 8:2286-91. 2002
    ..We investigated whether ERCC1 mRNA expression levels were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC)...
  49. pmc Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    M Reck
    Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf
    Ann Oncol 21:1804-9. 2010
    ..We report the final overall survival (OS) analysis from the phase III AVAiL trial...
  50. pmc Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
    Grace A McComsey
    Departments of Pediatrics and Medicine, Rainbow Babies and Children s Hospital, Case Western Reserve University, Cleveland, OH 44106, USA
    J Infect Dis 203:1791-801. 2011
    ..Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral density (BMD) have not been analyzed...
  51. ncbi Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
    ..Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS...
  52. pmc Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer
    Michael Graham Espey
    Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Free Radic Biol Med 50:1610-9. 2011
    ..These data support the testing of pharmacologic ascorbate in adjunctive treatments for cancers prone to high failure rates with conventional therapeutic regimens, such as pancreatic cancer...
  53. ncbi AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
    Sonya D Zabludoff
    AstraZeneca R and D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA
    Mol Cancer Ther 7:2955-66. 2008
    ....
  54. ncbi Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Y K Kang
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, Songpa Gu, Seoul, Republic of Korea
    Ann Oncol 20:666-73. 2009
    ..To compare capecitabine/cisplatin with 5-fluorouracil/cisplatin as first-line treatment for advanced gastric cancer (AGC)...
  55. ncbi Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:1452-9. 2009
    ..The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine...
  56. ncbi Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
    E Van Cutsem
    Department Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 22:1430-8. 2004
    ....
  57. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
    ..To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC)...
  58. ncbi Novel approaches to deliver gemcitabine to cancers
    L Harivardhan Reddy
    Univ Paris Sud XI, Faculte de Pharmacie, UMR CNRS 8612, 92296 Chatenay Malabry Cedex, France
    Curr Pharm Des 14:1124-37. 2008
    ..Altogether, the delivery strategies adopted for gemcitabine led to a considerable improvement in the treatment of cancers at the preclinical stage, and some of them are potential candidates for clinical trials...
  59. pmc Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Maurizio Scaltriti
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2688-95. 2010
    ..We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting...
  60. pmc Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers
    Liang Li
    Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 4:e7765. 2009
    ....
  61. ncbi Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Niall C Tebbutt
    Austin Health, Studley Rd, Heidelberg, Victoria, 3084, Australia
    J Clin Oncol 28:3191-8. 2010
    ..To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial...
  62. ncbi Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells
    Zhiyong Du
    Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University Medical School, 200025, Shanghai, People s Republic of China
    Dig Dis Sci 56:741-50. 2011
    ..Tumor resistance to chemoradiation therapy is partly attributed to the presence of apoptosis-resistant cancer stem cells (CSCs). Chemoradiation therapy can enrich CSCs by killing apoptosis-susceptible cancer cells...
  63. ncbi An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines
    Jennifer D Davidson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Cancer Res 64:3761-6. 2004
    ..The results from this study indicate that the level of RRM1 may affect gemcitabine response. Furthermore, RRM1 may serve as a biomarker for gemcitabine response...
  64. ncbi Nucleoside analogues: mechanisms of drug resistance and reversal strategies
    C M Galmarini
    , Laboratoire de Cytologie Analytique, , Lyon, France
    Leukemia 15:875-90. 2001
    ..Strategies aiming to increase the intracellular concentrations of active compounds are presented...
  65. ncbi Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 24:1898-903. 2006
    ....
  66. ncbi Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma
    Raphael Marechal
    Department of Gastroenterology and Gastrointestinal Cancer Unit, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium
    Gastroenterology 143:664-74.e1-6. 2012
    ..gemcitabine cytotoxicity include the activities of the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), and ribonucleotide reductase subunit 1 (RRM1)...
  67. ncbi Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Woodville, SA 5011 Australia
    J Clin Oncol 29:2675-82. 2011
    ....
  68. ncbi RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, MRC 4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 24:4731-7. 2006
    ..However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed...
  69. ncbi Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group
    Dorte Lisbet Nielsen
    Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
    J Clin Oncol 29:4748-54. 2011
    ..The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer...
  70. ncbi H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation
    Brett Ewald
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:1239-48. 2007
    ..Thus, H2AX becomes phosphorylated and forms nuclear foci in response to gemcitabine-induced stalled replication forks, and this is greatly increased upon checkpoint abrogation...
  71. ncbi Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine
    Takeo Shimasaki
    Department of Medical Oncology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    J Gastroenterol 47:321-33. 2012
    ..Here, we investigated the effect of GSK3β inhibition on pancreatic cancer cell sensitivity to gemcitabine and the underlying molecular mechanism...
  72. ncbi Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
    A F C Okines
    The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
    Ann Oncol 20:1529-34. 2009
    ....
  73. ncbi Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy
    Tsutomu Tanaka
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 38:755-61. 2008
    ..The purpose of the retrospective analysis is to elucidate the treatment efficacy and toxicity as well as to identify prognostic factors in Japanese patients with advanced pancreatic cancer treated with gemcitabine...
  74. ncbi Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:3853-61. 2007
    ..018 versus control). Overall, our results suggest that curcumin potentiates the antitumor effects of gemcitabine in pancreatic cancer by suppressing proliferation, angiogenesis, NF-kappaB, and NF-kappaB-regulated gene products...
  75. ncbi Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
    Kimberly Y Smith
    Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS 23:1547-56. 2009
    ..This is the first completed, randomized clinical trial to directly compare the efficacy, safety, and tolerability of these agents, each in combination with lopinavir/ritonavir in antiretroviral-naive patients...
  76. pmc XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    J Cassidy
    Institute of Cancer Sciences, Beatson Oncology Centre, 1053 Great Western Road, Glasgow G12 0YN, UK
    Br J Cancer 105:58-64. 2011
    ..We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer...
  77. pmc Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers
    Gaudensia Mutua
    Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya
    PLoS ONE 7:e33103. 2012
    ..We present safety and adherence data from the first trial of an intermittent PrEP regimen among Kenyan men who have sex with men (MSM) and female sex workers (FSW)...
  78. ncbi A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 68:157-64. 2011
    ..We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy...
  79. pmc Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2
    Surabhi Dangi-Garimella
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer Res 71:1019-28. 2011
    ....
  80. ncbi New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine
    Stephan A Veltkamp
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Mol Cancer Ther 7:2415-25. 2008
    ..dFdU-TP is incorporated into DNA and RNA, which correlated with dFdU cytotoxicity. These data provide strong evidence that dFdU can significantly contribute to the cytotoxicity of dFdC...
  81. pmc Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
    Meredith A Morgan
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109 5637, USA
    Cancer Res 70:4972-81. 2010
    ..Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer...
  82. ncbi Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review)
    Mariacristina Di Marco
    L e A Seràgnoli Department of Hematology and Oncological Sciences, S Orsola Malpighi Hospital, University of Bologna, I 40138 Bologna, Italy
    Oncol Rep 23:1183-92. 2010
    ..This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years...
  83. ncbi A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients
    Lai San Tham
    Department of Hematology Oncology, National University Hospital, Singapore
    Clin Cancer Res 14:4213-8. 2008
    ....
  84. ncbi Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
    Howard S Hochster
    New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA
    J Clin Oncol 26:3523-9. 2008
    ..To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC)...
  85. ncbi EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer
    Roderich E Schwarz
    Department of Surgery, Division of Surgical Oncology, UT Southwestern Medical Center, Dallas, TX, USA
    Ann Surg Oncol 17:1442-52. 2010
    ..We tested the hypothesis that a combination of EMAP with bevacizumab (Bev) and gemcitabine (Gem) targets different pathways of PDAC progression and represents more effective treatment...
  86. pmc Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression
    Liang Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:7050-8. 2008
    ..Our results suggest that cell-based model system studies, when combined with complementary functional characterization, may help to identify biomarkers for response to chemotherapy with these cytidine analogues...
  87. ncbi An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer
    Roderich E Schwarz
    Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8548, USA
    Surgery 146:241-9. 2009
    ..Combination treatments in addition to gemcitabine have failed to improve outcomes in pancreatic cancer. We tested gemcitabine in combination with the antiendothelial agent endothelial monocyte-activating polypeptide II (EMAP II)...
  88. pmc Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    PLoS Med 5:e28. 2008
    ..We evaluated daily and intermittent PrEP regimens of increasing antiviral activity in a macaque model that closely resembles human transmission...
  89. ncbi Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo
    Shuang Jia Wang
    Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, PR China
    Cancer Lett 293:99-108. 2010
    ..We concluded that inhibition of gemcitabine-induced NF-kappaB activation is one of the mechanisms that DHA dramatically promotes its anti-tumor effect on pancreatic cancer...
  90. ncbi Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine)
    Andries M Bergman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Drug Resist Updat 5:19-33. 2002
    ..this review, we summarize the pre-clinical mechanisms of acquired and inherent resistance to the fluorinated deoxycytidine analog gemcitabine (2',2'-difluorodeoxycytidine, dFdC, Gemzar((R))), which has proven activity in non-small ..
  91. doi Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study
    Charles S Fuchs
    J Clin Oncol 26:689-90. 2008
  92. pmc Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer
    Soley Bayraktar
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, United States
    World J Gastroenterol 16:673-82. 2010
    ..We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer...
  93. ncbi CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
    Sung Pil Hong
    Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
    Int J Cancer 125:2323-31. 2009
    ....
  94. pmc The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase
    Christina L Costantino
    Department of Surgery, Jefferson Center for Pancreatic, Biliary and Related Cancers, Departments of Pathology and Pharmacology and Experimental Therapeutics, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Cancer Res 69:4567-72. 2009
    ..In pancreatic cancer cells, HuR associates with deoxycytidine kinase (dCK) mRNA, which encodes the enzyme that metabolizes and thereby activates gemcitabine...
  95. ncbi Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer
    Sanjeev Banerjee
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 65:9064-72. 2005
    ....
  96. ncbi Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
    B Chauffert
    Department of Oncology, Anticancer Center G F Leclerc, Dijon, France
    Ann Oncol 19:1592-9. 2008
    ..The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain...
  97. pmc A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
    S R Bramhall
    Department of Surgery, Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK
    Br J Cancer 87:161-7. 2002
    ..The combination of marimastat with gemcitabine was well tolerated. Further studies of marimastat as a maintenance treatment following a response or stable disease on gemcitabine may be justified...
  98. pmc Adjuvant chemotherapy in older women with early-stage breast cancer
    Hyman B Muss
    University of Vermont, Burlington, USA
    N Engl J Med 360:2055-65. 2009
    ..We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older...
  99. ncbi Cellular pharmacology of gemcitabine
    E Mini
    Department of Pharmacology, University of Florence, Florence, Italy
    Ann Oncol 17:v7-12. 2006
    Gemcitabine (2',2'-difluoro 2'-deoxycytidine, dFdC) is the most important cytidine analogue developed since cytosine arabinoside (Ara-C)...
  100. ncbi Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil
    Nobuaki Kurata
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812 8582, Japan
    Int J Oncol 39:473-82. 2011
    ..05). In conclusion, pancreatic cancer cells showed no cross-resistance to GEM and 5-FU. Quantitative analyses of RRM1, TP, DPD and TS mRNA levels in pancreatic cancer cells may be useful for predicting their sensitivity to GEM and 5-FU...
  101. ncbi Chemoradiotherapy for unresectable pancreatic cancer
    Edgar Ben-Josef
    Department of Radiation Oncology, University of Michigan Medical Center, UH B2C490 1500 East Medical Center Drive, Ann Arbor, MI, 48109 0010, USA
    Int J Clin Oncol 13:121-6. 2008
    ..While it is clear that breakthroughs in treatment would come mostly from advances in systemic therapy, the evidence suggests that radiotherapy should not fall out of use, but rather be intensified...

Research Grants70

  1. Genistein and Prostate Cancer
    Rajvir Dahiya; Fiscal Year: 2010
    ..We will investigate whether genistein alone or in combination with demethylating agent (5-'-aza-2-deoxycytidine (5-AZA-C) and histone deacetylase inhibitor (trichostatin (TSA) can inhibit prostate cancer growth in vitro...
  2. SQUAMOUS CELL CARCINOMAS - EFFECTS OF RETINOIDS
    Lorraine J Gudas; Fiscal Year: 2013
    ..RA (all-trans retinoic acid) and/or 5-aza-dCdR (the DNA methyltransferase (DNMTase) inhibitor 5-aza-2'-deoxycytidine) inhibit or delay the development of oral cavity SCC (squamous cell carcinoma)...
  3. Vitamin D in Prostate Cancer: Tumor Vasculature Effects
    Candace S Johnson; Fiscal Year: 2012
    ..Treatment of TDEC with the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, restores calcitriol-mediated induction of CYP24 and resistance to calcitriol...
  4. Diet and Alcohol Induced Epigenetic Changes in Oral Cavity Carcinogenesis Model
    Lorraine J Gudas; Fiscal Year: 2013
    ..stem/progenitor cells is influenced by carcinogens, alcohol, and drugs, such as zebularine and 5-aza-2'-deoxycytidine, which have been shown both to inhibit DNA methyltransferases and to reduce tumor incidence in other ..
  5. AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
    MARKUS MUSCHEN; Fiscal Year: 2013
    ..Aim 4: Prodrug-based targeting of AID-expressing Ph+ ALL cells: AID can deaminate monomeric deoxycytidine to deoxyuracil...
  6. Epigenetic Regulation of Acute Lung Injury Resolution
    Benjamin Singer; Fiscal Year: 2013
    ..The candidate has preliminary data demonstrating that a chromatin-modifying drug (5-aza-2'-deoxycytidine [AZA]) enhances resolution of ALI in mice and increases the number of Tregs in their lungs...
  7. Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
    Andrew D Weinberg; Fiscal Year: 2012
    ..Agonox is proposing to genetically engineer the mouse antibody to become more "human" so that several rounds of treatment may be administered in order to achieve an even better outcome for cancer patients in future clinical trials. ..
  8. Epigenetic modification of endothelial progenitor cells into multipotent cells
    Rajasingh Johnson; Fiscal Year: 2010
    ..treatment of EPC with chromatin modifying agents Trichostatin A (inhibitor for histone deacetylase) and 5Aza-2-deoxycytidine (inhibitor for DNA methylation) influence histone acetylation and DNA methylation respectively thereby modify ..
  9. Epigenetic regulation of HIV latency
    ERIC M VERDIN; Fiscal Year: 2013
    ..We also found that the inhibitor of DNA methylation, 5-aza-2'deoxycytidine (aza-CdR), synergizes with NF-B activators to reactivate latent HIV...
  10. The role of Immunoglobulin CDRH3 in Autoimmune Disease
    HARRY WILLIAM SCHROEDER; Fiscal Year: 2012
    ..We predict that the information we glean from our studies will help us learn how to prevent lupus, as well as control humoral responses to pathogens, vaccines, and altered-self antigens. ..
  11. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes
    David R Clemmons; Fiscal Year: 2010
    ..This project is seeking to develop a drug that will specifically inhibit the progression of atherosclerosis in patients with diabetes and that has the potential to prevent these complications. ..
  12. Pharmacogenetics of Ara-C Metabolic Pathway
    Jatinder K Lamba; Fiscal Year: 2012
    ..of this research is that genetic polymorphisms in key genes in the ara-C metabolic pathway -specifically: deoxycytidine kinase (DCK, a rate limiting activating enzyme);5'nucleotidase (NT5C2), deoxycytidine deaminase (CDA), ..
  13. Mucosal Immune Ontogeny and Intestinal Microbiota in Infants
    Edward N Janoff; Fiscal Year: 2010
    ..Children are particularly susceptible to mucosal infections. We do not as yet know how the immune response, which protects us against infections, develops in children. This proposal addresses this issue. ..
  14. Engineering enzymes for anti-tumor suicide gene therapy
    Barry L Stoddard; Fiscal Year: 2010
    ..are engineering and optimizing two nucleoside salvage/synthesis enzymes for PGT: cytosine deaminase (CD) and deoxycytidine kinase (dCK)...
  15. Longitudinal study of membrane lipids: pre-clinical Alzheimer's biomarkers
    Michelle M Mielke; Fiscal Year: 2010
    ....
  16. A high throughput screen for X-reactivation and reprogramming by small molecules
    Jeannie T Lee; Fiscal Year: 2013
    ..A few small molecules, including the DNA-methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-aza-dC), have been identified that partially de-repress genes on the inactive X in somatic cells and that ..
  17. Isolation of a cervical cancer tumor suppressor gene
    Eri S Srivatsan; Fiscal Year: 2012
    ..Reexpression of cystatin E/M was observed after 5'aza 2-deoxycytidine and/or Trichostatin A treatment of cervical cancer cell lines confirming the presence of promoter ..
  18. Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker
    Suzanne Craft; Fiscal Year: 2013
    ..abstract_text> ..
  19. Maintenance therapy with decitabine for acute myeloid leukemia in first remission
    William G Blum; Fiscal Year: 2010
    ..and other myeloid disorders is the DNA methyltransferase inhibitor (DNMT) inhibitor decitabine, 5-aza-2'-deoxycytidine.[5-10] Decitabine has significant activity in AML and myelodysplastic syndrome (MDS) when given at low doses (..
  20. G-protein coupled receptor-30(GPR30):a putative new therapeutic target for PCa
    Shuk Mei Ho; Fiscal Year: 2013
    ..Treatment of PCa cells with 5-aza-2'-deoxycytidine, a demethylating agent, tricostatinA, a HDACi, or an ADT increased GPR30 expression...
  21. MYCN Function in Neuroblastoma
    Naohiko Ikegaki; Fiscal Year: 2012
    ..a site-specific DNA demethylation inducer in combination with DNA methylation inhibitors (5-Aza-2'- deoxycytidine and RG108) and RAS pathway specific MYCN protein destabilizers in preclinical human NB subcutaneous and ..
  22. Biology of Alpha Particle Immunotherapy
    David A Scheinberg; Fiscal Year: 2013
    ..The long- term goals of the project are to develop simple targeting vehicles that kill via alpha particle emission and that make use of our understanding of the tumor's response to alpha particle damage. ..
  23. Anaerobic shock as a novel treatment for tuberculosis
    Xilin Zhao; Fiscal Year: 2010
    ..The present program seeks to develop a novel, rapid, and highly efficient treatment of tuberculosis upon induction of self-destructive autolysis of Mycobacterium tuberculosis. ..
  24. Therapeutic Effects of Cataract Removal in Alzheimer's Disease
    GROVER CLEVELAND GILMORE; Fiscal Year: 2013
    ..The study will demonstrate the clinical efficacy of cataract removal as a direct intervention to potentially improve the visual and cognitive functions, and the quality of life in persons diagnosed with AD. ..
  25. Role of IG CDR-H3 in Responses to HIV Vaccines
    HARRY WILLIAM SCHROEDER; Fiscal Year: 2013
    ..g. antigen encased in liposomes or antigen displayed by pseudovirions) will facilitate the generation of antibodies that can bind the key MPER region of the HIV envelope protein in a way that will enable them to broadly neutralize HIV. ..
  26. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy
    Kate Rittenhouse-Olson; Fiscal Year: 2013
    ..Phase III studies will involve clinical testing. Potential partnering or out-licensing points for pharmaceutical company facilitation of commercialization of JAA-F11 can occur after each completed phase of the overall project. ..
  27. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter A Jones; Fiscal Year: 2013
    ..Achievement of these aims should have major impact in our understanding of the epigenetics of cancer and have direct relevance to new strategies to treat and prevent cancer. ..
  28. MOLECULAR ANALYSIS OF CD8, MHC CLASS I INTERACTION
    Paula B Kavathas; Fiscal Year: 2012
    ....
  29. Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity
    MARIO LUIS SANTIAGO; Fiscal Year: 2013
    ..We recently identified Rfv3 as Apobec3, a deoxycytidine deaminase with broad activity against retroviruses, including HIV-1 (Santiago ML et al. 2008...
  30. Virotherapy for pancreatic cancer with wildtype and armed Myxoma viruses
    Grant McFadden; Fiscal Year: 2012
    ..Recombinant "armed" MYXVs that express deoxycytidine kinase (CDK) or the human equilibrative nucleoside transporter 1(hENT-1) will be engineered...
  31. Epigenetic alterations underlying tumorigenic potential of Glioblastoma Cells
    Theresa K Kelly; Fiscal Year: 2012
    ..Here I will investigate several levels of epigenetic regulation and how they are altered in brain tumors. ..
  32. Structure/function studies of nucleoside analog activating enzymes
    Arnon Lavie; Fiscal Year: 2009
    ..The enzyme deoxycytidine kinase (dCK) is the most important kinase in terms of nucleoside analog activation...
  33. CITALOPRAM DECREASES CSF AB: A RANDOMIZED DOSE FINDING TRIAL
    Yvette I Sheline; Fiscal Year: 2013
    ....
  34. Conversational Engagement as a Means to Delay Alzheimer's Disease Onset
    HIROKO HAYAMA DODGE; Fiscal Year: 2012
    ..The project is of high public health significance in that few effective, low-cost interventions exist for this vulnerable population. ..
  35. Novel Approaches to Screening for Inflicted Childhood Neurotrauma
    Rachel P Berger; Fiscal Year: 2013
    ..The goal of our study is to find ways to help doctors identify shaken baby syndrome when it initially presents before children are re-injured and/or killed. ..
  36. Prediction of the Structure of Therapeutic Antibodies with their Antigens
    Jeffrey J Gray; Fiscal Year: 2013
    ..Ultimately, these studies will yield insights into immunology, molecular recognition, and design of protein-protein interfaces and vaccines. ..
  37. Randomized study of combined epigenetic therapy
    Jean Pierre J Issa; Fiscal Year: 2011
    ..have shown substantial activity in hematologic malignancies and two of them, azacytidine and 5- aza-2'-deoxycytidine (DAC) are now FDA approved for the treatment of the myelodysplastic syndrome (MDS)...
  38. Molecular studies of lipid presentation and T cell recognition of CD1c
    ERIN JUNE ADAMS; Fiscal Year: 2013
    ..tuberculosis) are already evident. Our proposal will expand our understanding of CD1c lipid presentation and the T cells that are reactive to it. ..
  39. Structural and Mechanistic Studies of Error-Prone Polymerases
    Janice D Pata; Fiscal Year: 2012
    ..that belong to the DinB subfamily are able to bypass damaged deoxyguanosine bases accurately by incorporating deoxycytidine nucleotides opposite the lesion...
  40. Enzyme-delivery scaffold technology for targeted cancer killing.
    Arnon Lavie; Fiscal Year: 2013
    ..To test our technology, we will deliver an engineered version of human deoxycytidine kinase (dCKEN), which is a novel enzyme variant that has been endowed with thymidine kinase activity...
  41. Characterization of Pathogenic T cells in Alopecia Areata
    EMANUAL M MAVERAKIS; Fiscal Year: 2012
    ..We propose to study these T cells to determine how the autoimmune disease response evolves over time. We will also characterize the surface of the autoreactive T cells and the molecules they secrete. ..
  42. Identification and characterization of genes in del(5q) myelodysplastic syndrome
    Daniel Starczynowski; Fiscal Year: 2013
    ..Given that the molecular basis of MDS is poorly defined, we hope that characterization of TIFAB will facilitate understanding the molecular defects and the design of novel therapeutics in MDS. ..
  43. MRI-Compatible Fiber-Optically Sensorized Biopsy Needles for Oncological Applicat
    BEHZAD MOSLEHI; Fiscal Year: 2013
    ..The proposed work will advance the field of smart needle development for robotic surgery with potentially broad-based spin-off applications in oncology, biological imaging and bioengineering. ..
  44. Clinical Decision Rules to Discriminate Bruising Caused by Physical Child Abuse
    Mary Clyde Pierce; Fiscal Year: 2013
    ....
  45. Inhibition of heteromeric erbB kinases
    Mark I Greene; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: We are developing new classes of antibody therapeutics to treat breast cancers that have become resistant to therapeutics such as Herceptin or tyrosine kinase inhibitors. ..
  46. The NEIGHBORHOOD: POAG Heritable Overall Operational Database
    Janey L Wiggs; Fiscal Year: 2013
    ..Additionally, this proposal will form the basis of future studies of other POAG related traits and gene-gene and gene-environment interactions for CDR and POAG. ..
  47. Functional Decline in Three Dementia Types
    WALTER ANTHONY KUKULL; Fiscal Year: 2012
    ..The results of this study may assist clinicians and family caregivers to anticipate and plan for a demented individual's need for help with activities of daily living. ..
  48. Small molecular weight targeted killing agents against a periodontal pathogen
    Mark J Young; Fiscal Year: 2013
    ....
  49. Age related Cognitive Loss in Mumbai, India
    Dushyant P Purohit; Fiscal Year: 2010
    ..The methodology we propose is patterned on that of the Clinical, Neuropathology, Database, and Education and Information Transfer Cores of the Mount Sinai ADRC, an established, effective and highly productive NIA-funded ADRC. ..
  50. Innovative methods for modeling longitudianl medical costs
    Lei Liu; Fiscal Year: 2013
    ..abstract_text> ..
  51. Inhibition of HIV by GPI-anchored Antibody Derivatives
    Jason T Kimata; Fiscal Year: 2013
    ..S. and China to facilitate the development of novel gene therapy based HIV inhibitors. It therefore is within the goals of the U.S.-China Program for Biomedical Collaborative Research, RFA-AI-12-021. ..
  52. HIV-1 Neutralizing Antibody Binding to Viral Membrane Mimics
    Stefan Zauscher; Fiscal Year: 2013
    ..The antigen paired with an optimal lipid environment is more likely to induce the required polyreactive antibodies. ..
  53. TARGETING THE B-CELL RECPTOR COMPLEX AND DOWNSTREATM KINASES
    Sydney Welt; Fiscal Year: 2010
    ..Here we describe a strategy to target the BCRC and thus theoretically target every cell in these malignancies. The ability to cure these diseases will be dependent on the success of eradication of all tumor cells. ..
  54. Measuring change in Alzheimer's disease dysfunction more precisely with IRT
    Steve Balsis; Fiscal Year: 2012
    ....
  55. Targeted Therapy of B-cell Malignancies
    David Goldenberg; Fiscal Year: 2009
    ..Collectively, the integration of all of these different, but related endeavors promises to provide new knowledge and strategies for the improved management of B-cell malignancies. ..
  56. Structure and Function of MHC Proteins
    Lawrence J Stern; Fiscal Year: 2013
    ..The fifth aim is to characterize the structural basis for T cell crossreactivity of epitopes from vaccina virus and lymphocytic choriomeningitis virus. ..
  57. Storage and Distribution of Clinical Agents
    Young Kim; Fiscal Year: 2009
    ..Individual, blinded container labels are printed and checked, and the appropriate product (agent or placebo) pulled, labeled, and checked by a pharmacist before shipping to the investigator. ..
  58. Storage and Distribution of Clinical Agents
    Young Kim; Fiscal Year: 2010
    ..Individual, blinded container labels are printed and checked, and the appropriate product (agent or placebo) pulled, labeled, and checked by a pharmacist before shipping to the investigator. ..
  59. Storage and Distribution of Clinical Agents
    Young Kim; Fiscal Year: 2011
    ..Individual, blinded container labels are printed and checked, and the appropriate product (agent or placebo) pulled, labeled, and checked by a pharmacist before shipping to the investigator. ..
  60. Physical basis for T cell receptor binding and activity
    Brian M Baker; Fiscal Year: 2012
    ....
  61. Effect of Aerobic Exercise on Alzheimer's Pathophysiology in Preclinical AD
    JEFFREY MURRAY BURNS; Fiscal Year: 2013
    ....
  62. Immunoglobulin CDR-H3 and neutralizing antibodies to HIV
    Harry Schroeder; Fiscal Year: 2009
    ....
  63. PHARMACOLOGY OF DIDEOXYNUCLEOSIDES IN SMALL INTESTINAL
    JESSIE AU; Fiscal Year: 1991
    ..Examine the effects of ddNS on the levels and metabolism of endogenous pyrimidines and purines (thymidine, deoxycytidine, deoxyinosine, deoxyadenosine and adenosine), and the incorporation of DNA precursor (Deoxyguanosine) and RNA ..
  64. PATHOGENESIS AND PREVENTION OF IDDM
    Hugh McDevitt; Fiscal Year: 2002
    ..These studies will rely on the same techniques used by Drs. Chien and Davis to trace the development of islet cell specific T cells in the NOD mouse. ..
  65. ROLE OF THE GALLBLADDER IN PATHOGENESIS OF GALLSTONES
    LESTER WILLIAMS; Fiscal Year: 1991
    ..If abnormalities are, in fact, mediated by PG's, these studies could provide the potential for preventing CHL GS formation in individuals at high risk...
  66. MECHANISM UNDERLYING DCYVD MEDIATED PREFERENTIAL STIMULA
    Kapil Bhalla; Fiscal Year: 1993
    The aim of this proposal is to evaluate the role of deoxycytidine (dCyd) as a growth protective agent for normal myeloid progenitor cells in antileukemic regimens consisting of dCyd analogs, or other pyrimidine antagonists, and high dose ..
  67. Mechanisms of Cutaneous Drug Reactions
    CRAIG SVENSSON; Fiscal Year: 2004
    ..Moreover, they should enable us to develop in vitro screening tests that will permit the pre-clinical identification of drugs likely to pose a significant risk for the development of such reactions. ..
  68. ACTIVATION OF CHEMOTHERAPEUTIC AGENTS IN LEUKEMIC CELLS
    Donna Shewach; Fiscal Year: 1992
    ..such as deoxyguanosine, guanine arabinoside (araG) and cytosine arabinoside (araC) require activation by deoxycytidine kinase for anti-tumor activity...
  69. Chemical Pathology of 5-aza-2'-deoxycytidine
    Lawrence Sowers; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): The nucleoside analogue, 5-aza-2'-deoxycytidine (DAC) is an investigational agent for the treatment of sickle cell anemia as well as advanced human malignancies...
  70. MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
    Edward Newman; Fiscal Year: 2001
    5-Aza-2'-deoxycytidine (DAC) is an investigational agent with demonstrated activity in the treatment of acute myeloid leukemia and likely therapeutic utility in other leukemias and myelodysplastic syndromes...